JDM update September 2014 by Clarissa Pilkington
INVITED SPEAKER PRESENTATION Open Access
JDM update September 2014
Clarissa Pilkington
From 21st European Pediatric Rheumatology (PReS) Congress
Belgrade, Serbia. 17-21 September 2014
Aim
To review work in the field of JDM over the last 10
years, and to give an update on the progress of work
that is being undertaken in 2014.
Introduction
JDM is the commonest inflammatory myopathy of
childhood and has a wide variation in disease severity
and disease course. Collaborative work has moved forward
the understanding and the management of JDM in the last
10-15 years.
Review of international collaborative work
International groups have developed tools for the assess-
ment of muscles, as well as the assessment of disease
activity and disease damage. This has allowed physicians
to standardise their patient assessments. Core outcome
variables for JDM have been proposed (IMACS and
PRINTO) as well as definitions of disease flare and
remission. Work is going on to agree definitions of
improvement to help future treatment trials.
Diagnostic criteria continue to be based on those of
Bohan and Peter, but an international survey in 2006
proposed adding items such as MRI and capillaroscopy.
An IMACS collaboration has produced a proposed new
Classification Criteria which should allow more accurate
delineation of cases for future research.
This international work has enabled the first interna-
tional RCT in treatment-resistant DM and JDM to be
undertaken, and for PRINTO to conduct a trial of treat-
ment in new onset cases of JDM. National collaborative
efforts have led to setting up registries and cohort studies,
allowing better understanding of variation in disease and
variation in disease management.
Consensus work has also produced a muscle biopsy
score, treatment guidelines to allow comparison of
patients within normal clinical practice (CARRA), whilst
the SHARE project will produce a European concensus on
treatment advice. Work is being undertaken to produce an
MRI scoring system; as well as work to agree the mini-
mum data that needs to be collected by physicians caring
for JDM (i.e. minimum standards of care).
Laboratory research on myositis specific autoantibodies
in JDM is beginning to define different subgroups of JDM
patients. This may lead to a better stratification of disease
severity and prognosis. This would enable physicians to
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